Key Documents

View All Documentation

S8442

SU 5416

Name: SU 5416
Brand: SIGMA

≥98% (HPLC), powder, neuronal nitric oxide synthase inhibitor

Synonym(s):

1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₅H₁₄N₂O

CAS Number:

204005-46-9

Molecular Weight:

238.28

UNSPSC Code:

51111800

PubChem Substance ID:

24278606

NACRES:

NA.77

MDL number:

MFCD01940922

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

SU 5416, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

yellow to yellow-orange

mp

221-222 °C

solubility

DMSO: 20 mg/mL, clear (warmed), H₂O: insoluble

storage temp.

−20°C

SMILES string

Cc1cc(C)c(C=C2C(=O)Nc3ccccc23)[nH]1

InChI

1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8+

InChI key

WUWDLXZGHZSWQZ-XYOKQWHBSA-N

Gene Information

human ... EGFR(1956), FLT1(2321), IGFBP1(3484), IL2(3558), KDR(3791), PDGFRB(5159)
mouse ... Flt1(14254), Kdr(16542)

Description

General description

SU 5416 is a vascular endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 inhibitor. SU 5416 is known to prevent tumor growth and tumor angiogenesis. SU 5416 inhibits the activity of neuronal nitric oxide synthase and protects the neuronal cells from nitric oxide-mediated neurotoxicity. It also acts as an agonist of aryl hydrocarbon receptor and may be an effective clinical agent for treating autoimmune diseases and transplant rejection.

Application

SU 5416 has been used to treat HUVEC cells before the tube formation assay to assess its impact on the network generated from tube formation. to induce pulmonary hypertension (PH) in mice to serve as an experimental model

Biochem/physiol Actions

SU 516 inhibits the activity of neuronal nitric oxide synthase and protects the neuronal cells from nitric oxide-mediated neurotoxicity.¹ It also acts an agonist of aryl hydrocarbon receptor and is an effective clinical agent for treating autoimmune diseases and transplant rejection.²

SU 5416 is a vascular endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 inhibitor.

Features and Benefits

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Storage Class

11 - Combustible Solids

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

A VEGF-A/SOX2/SRSF2 network controls VEGFR1 pre-mRNA alternative splicing in lung carcinoma cells.

Cherine Abou Faycal et al.

Scientific reports, 9(1), 336-336 (2019-01-25)

The splice variant sVEGFR1-i13 is a truncated version of the cell membrane-spanning VEGFR1 receptor that is devoid of its transmembrane and tyrosine kinase domains. We recently showed the contribution of sVEGFR1-i13 to the progression and the response of squamous lung

SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation.

Joshua D Mezrich et al.

PloS one, 7(9), e44547-e44547 (2012-09-13)

The experimental compound SU5416 went as far as Phase III clinical trials as an anticancer agent, putatively because of its activity as a VEGFR-2 inhibitor, but showed poor results. Here, we show that SU5416 is also an aryl hydrocarbon receptor

A novel murine model of severe pulmonary arterial hypertension.

Loredana Ciuclan et al.

American journal of respiratory and critical care medicine, 184(10), 1171-1182 (2011-08-27)

The complex pathologies associated with severe pulmonary arterial hypertension (PAH) in humans have been a challenge to reproduce in mice due to the subtle phenotype displayed to PAH stimuli. Here we aim to develop a novel murine model of PAH

View All Related Papers

Global Trade Item Number

SKU	GTIN
S8442-25MG	04061836960797
S8442-5MG	04061836960803